Karuna Therapeutics, Inc. is making waves in the field of clinical-stage biopharmaceuticals, with a focus on delivering transformative medicines to those living with psychiatric and neurological conditions. The company's lead product, KarXT, which is an oral modulator of muscarinic receptors, is currently in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia. It is also being developed for various central nervous system disorders, including negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of peripheral tissues and dementia-related psychosis, such as Alzheimer's disease. In addition to KarXT, Karuna Therapeutics is exploring other muscarinic-targeted drug candidates, with a plan to develop TRPC4/5 and KAR-2618 as lead candidates for the treatment of mood and anxiety disorders. The company has license agreements with Eli Lilly and Company and Zai Lab (Shanghai) Co., Ltd, a patent license agreement with PureTech Health LLC, and drug discovery partnerships with Charles River Laboratories and PsychoGenics, Inc. Founded in 2009 and headquartered in Boston, Massachusetts, Karuna Therapeutics was formerly known as Karuna Pharmaceuticals, Inc. before changing its name in March 2019. The company's commitment to creating innovative treatments for those with psychiatric and neurological conditions has solidified its position as a notable player in the biopharmaceutical industry.